Korro Bio, Inc. (KRRO) is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company developing a new class of genetic medicines based on RNA editing. Using its OPERA (Oligonucleotide Promoted Editing of RNA) platform, the company aims to make precise, single-base edits to RNA — a transient, non-permanent approach that differs from traditional DNA-editing technologies. The stock has traded in a wide range over the past year as the pipeline has evolved, and investors are now weighing whether shares can climb toward a $20 price target.
The $20 central target reflects 11 individually verifiable analyst price targets rather than any single published consensus figure. The range is wide — from $10 at RBC Capital to $30 at Piper Sandler — which captures the genuine disagreement about the company's risk and reward.
At the bullish end, Piper Sandler's Yasmeen Rahimi holds an Overweight rating with a $30 target. Raymond James and JonesTrading each stand at $23, while Oppenheimer and Cantor Fitzgerald are at $22. Citi (initiated by Yigal Nochomovitz) and LifeSci Capital sit at $21, Clear Street at $18, and H.C. Wainwright and Chardan Capital at $15. RBC Capital's $10 hold is the lone cautious stance. Averaging these 11 targets produces a mean of $20.00, which rounds cleanly to the $20 used here.
The dispersion traces back to November 2025, when a disappointing alpha-1 antitrypsin deficiency (AATD) readout for KRRO-110 triggered a sharp selloff, layoffs, and steep downgrades. Sentiment rebounded through early 2026 as the company refocused on KRRO-121 for hyperammonemia and extended its cash runway, prompting a wave of upgrades. The average analyst price target has since recovered, but the spread between $10 and $30 shows analysts still disagree sharply on the platform's value.
Shares closed at $15.73 on November 10, 2026, giving the company a market capitalization of roughly $216 million. Reaching $20 requires a move of about 27%, which represents a substantial advance for a clinical-stage biotech — achievable only if clinical and corporate catalysts reinforce the bull case.
Korro Bio is pre-commercial, with roughly $1.3 million in trailing collaboration revenue and a net loss near $106 million over the trailing twelve months, or negative EPS (earnings per share) of about $8.89. The company held approximately $105 million in cash, supported by an $85 million financing that management has said extends the runway into 2028. The path toward $20 therefore depends less on near-term earnings and more on de-risking KRRO-121, advancing earlier-stage programs, and preserving balance-sheet flexibility.
The stock's 52-week range spans roughly $5.20 to $33.92, illustrating extreme volatility. Shares have consolidated above the $14–$15 area in recent sessions, a zone that could act as near-term support. On the upside, $20 is both the round-number level and the average analyst price target, potentially making it a meaningful resistance area; beyond that sits the $30-plus region near the prior 52-week high. The wide trading range suggests the market is still repricing the company's post-readout strategy.
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual assumptions vary. Investors should watch quarterly results and cash-burn disclosures, clinical updates and regulatory milestones for KRRO-121, any changes to the Novo Nordisk collaboration, financing activity, and analyst target revisions. Given how reactive this stock has been to news flow, clinical data and guidance on the runway will matter most to the $20 question.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, track existing positions, and spot changing trends more efficiently than manual review allows. For investors following Korro Bio and other volatile equities, pairing AI signals with their own research can help filter the noise of day-to-day price movement.
Can KRRO reach $20? The question is credible but not guaranteed. The target is the mean of 11 verified analyst targets spanning $10 to $30, and it sits about 27% above the latest close. The bull case rests on the OPERA platform, KRRO-121's progression, the Novo Nordisk collaboration, and an extended cash runway. The bear case rests on a pre-revenue profile, the KRRO-110 failure, cash burn, and genuine analyst disagreement. The wide dispersion — with RBC Capital at $10 and Piper Sandler at $30 — underscores that this is a high-risk, catalyst-driven story, not a near-certainty. Investors should monitor clinical milestones and balance-sheet developments closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, KRRO has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if KRRO jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To KRRO | 1D Price Change % | ||
|---|---|---|---|---|
| KRRO | 100% | +0.97% | ||
| EDIT - KRRO | 49% Loosely correlated | -3.01% | ||
| RCKT - KRRO | 46% Loosely correlated | N/A | ||
| MGNX - KRRO | 45% Loosely correlated | -3.90% | ||
| TRDA - KRRO | 43% Loosely correlated | +1.41% | ||
| DNLI - KRRO | 39% Loosely correlated | +2.22% | ||
More | ||||